Anticancer agent 258
Anticancer agent 258 is an imidazo [1,2-B][1,2,4] triazol derivative. Anticancer agent 258 regulates the activity of nuclear receptors. Anticancer agent 258 has an EC50 of 63 nM against Nurr in N2A cells. Anticancer agent 258 has IC50 of 0.1 pM for Nur77 in HEK293 cells. Anticancer agent 258 can be used in the study of cancer, metabolic diseases and neurological disorders[1].
Product Specifications
CAS Number
2891984-12-4
UNSPSC
12352005
Target
Nuclear Hormone Receptor 4A/NR4A; Orphan Receptor
Related Pathways
GPCR/G Protein; Vitamin D Related/Nuclear Receptor
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cancer; Metabolic Disease; Neurological Disease
Smiles
FC1=CC=C(C2=NN(C=C(N3C)C4=CC(F)=CC=C4)C3=N2)C=C1
Molecular Formula
C17H12F2N4
Molecular Weight
310.30
References & Citations
[1]Antonio ALMARIO, et al. Imidazo[1,2-b][1,2,4]triazol derivatives for use in therapy. US20240300956A1. 2024-09-12.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
(6- (4- (Trifluoromethoxy) phenoxy) pyridin-3-yl) boronic acid
(6- (4- (Trifluoromethoxy) phenoxy) pyridin-3-yl) boronic acid
(6- (4- (Trifluoromethoxy) phenoxy) pyridin-3-yl) boronic acid
